These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy. Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735 [No Abstract] [Full Text] [Related]
24. Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts. Alamartine E; Bellakoul R; Berthoux F Transplant Proc; 1994 Feb; 26(1):273-4. PubMed ID: 8108975 [No Abstract] [Full Text] [Related]
25. Prophylaxis of human cytomegalovirus infection in renal transplant patients with valacyclovir and ganciclovir. Zhang P; Wang W; Zhang L; Li SF; Guan LB; Dong LQ; Zhou S; Yu P Acta Virol; 2013; 57(3):375-7. PubMed ID: 24020766 [No Abstract] [Full Text] [Related]
26. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies. Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495 [TBL] [Abstract][Full Text] [Related]
27. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021 [TBL] [Abstract][Full Text] [Related]
28. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients. Israni A; Krok K; Cohen D; Blumberg E; Bloom RD Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685 [TBL] [Abstract][Full Text] [Related]
30. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease]. Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888 [TBL] [Abstract][Full Text] [Related]
31. Incidence of infection and acute rejection after cytomegalovirus immune globulin prophylaxis in renal transplantation. Basadonna G; Feria A; Perez R; Klein H; Sturges M; Colquhoun S Transplant Proc; 1994 Oct; 26(5 Suppl 1):52-3. PubMed ID: 7940976 [No Abstract] [Full Text] [Related]
32. Delayed use of OKT3 for severe acute tubular necrosis in renal transplantation. VanderWerf BA Transplant Proc; 1996 Aug; 28(4):2115-6. PubMed ID: 8769172 [No Abstract] [Full Text] [Related]
33. Treatment of cytomegalovirus infections with gancyclovir during OKT3 administration. Haberal M; Velidedoğlu E; Arslan G; Bilgin N; Büyükpamukçu N; Karamehmetoğlu M Transplant Proc; 1995 Oct; 27(5):2707. PubMed ID: 7482883 [No Abstract] [Full Text] [Related]
34. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience. Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494 [No Abstract] [Full Text] [Related]
35. CMV in kidney transplantation: a single center experience over 22 years. Nashan B; Lück R; Kliem V; Brunkhorst R; Schlitt HJ; Klempnauer J Clin Transpl; 1999; ():181-8. PubMed ID: 11038636 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Ahsan N; Holman MJ; Yang HC Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of infections in renal transplant recipients treated with cyclosporine. Carmellini M; Romagnoli J; Pietrabissa A; Di Stefano R; Oleggini M; Rindi P; Rizzo G; Mosca F Transplant Proc; 1994 Oct; 26(5):2658-9. PubMed ID: 7940832 [No Abstract] [Full Text] [Related]
38. [Muromonab CD3]. Akioka Y; Hattori M; Ito K Nihon Rinsho; 2005 May; 63 Suppl 5():747-50. PubMed ID: 15954439 [No Abstract] [Full Text] [Related]
39. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation. McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724 [TBL] [Abstract][Full Text] [Related]
40. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function. Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]